Published in J Immunol on November 01, 1975
Active suppression of in vitro reactivity of spleen cells after BCG treatment. Immunology (1978) 1.55
Induction of suppressor T cells in delayed-type hypersensitivity to Mycobacterium bovis BCG in low-responder mice. Infect Immun (1980) 1.48
Opposite effects of BCG on spleen and lymph node cells: lymphocyte proliferation and immunoglobulin synthesis. Infect Immun (1978) 1.29
Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res (2012) 1.23
Mechanisms of trypanosome-mediated suppression of humoral immunity in mice. Proc Natl Acad Sci U S A (1978) 1.18
Visceral leishmaniasis in congenic mice of susceptible and resistant phenotypes: immunosuppression by adherent spleen cells. Infect Immun (1985) 1.15
The adjuvant effect of Corynebacterium parvum: T-cell dependence of macrophage activation. J Exp Med (1977) 1.11
Depression by Pseudomonas aeruginosa of two T-cell-mediated responses, anti-Listeria immunity and delayed-type hypersensitivity to sheep erythrocytes. Infect Immun (1982) 1.09
Nonspecific suppression of primary antibody responses and presence of plastic-adherent suppressor cells in Toxoplasma gondii-infected mice. Infect Immun (1981) 1.05
Suppression of in vitro lymphocyte proliferation in C57BL/10 ScN mice vaccinated with phase I Coxiella burnetii. Infect Immun (1985) 1.05
Suppression of BCG cell wall induced delayed-type hypersensitivity by BCG pre-treatment. I. Induction of adherent suppressor cells by live BCG injection and their characterization. Immunology (1981) 1.04
IFN-beta-induced reduction of superoxide anion generation by macrophages. Immunology (1982) 1.04
Macromolecular inhibitory factor for lymphoid cells produced by mouse macrophages. Immunology (1977) 0.99
Conversion of soluble immune response suppressor to macrophage-derived suppressor factor by peroxide. Proc Natl Acad Sci U S A (1981) 0.93
Interferon decreases production of hydrogen peroxide by macrophages: correlation with reduction of suppressive capacity and of anti-microbial activity. Immunology (1983) 0.93
Suppression of BCG cell wall-induced delayed-type hypersensitivity by BCG pre-treatment. II. Induction of suppressor T cells by heat-killed BCG injection. Immunology (1982) 0.90
Suppression of unprimed T and B cells in antibody responses by irradiation-resistant and plastic-adherent suppressor cells in Toxoplasma gondii-infected mice. Infect Immun (1983) 0.89
Characteristics of resistance to Listeria monocytogenes enhanced by Corynebacterium parvum in mice. Immunology (1980) 0.88
Involvement of prostaglandin E1 in delayed-type hypersensitivity suppression induced with live Mycobacterium bovis BCG. Infect Immun (1982) 0.86
Non-specific cytotoxicity of spleen cells in mice bearing transplanted chemically induced fibrosarcomas. Br J Cancer (1977) 0.83
In vitro suppression of T-cell mitogenic response and tumor cell proliferation by spleen macrophages from normal chickens. Infect Immun (1980) 0.82
Protection of mice against mouse hepatitis virus by Corynebacterium parvum. Infect Immun (1981) 0.82
Nonspecific suppression of initiation of memory cells in Toxoplasma gondii-infected mice. Infect Immun (1981) 0.81
Murine macrophage-lymphocyte interactions: scanning electron microscopic study. Infect Immun (1978) 0.81
Activation of K cells in mice with transplanted tumours differing in immunogenicity and metastasizing capacity. Br J Cancer (1977) 0.80
Paradoxical presence of T cell anergy during successful T cell-dependent tumour immunotherapy: characterization of a state of T cell 'amnaesia' following systemic administration of C. parvum. Clin Exp Immunol (1984) 0.80
Interferon production and lymphocyte stimulation in human leucocyte cultures stimulated by Corynebacterium parvum. Clin Exp Immunol (1978) 0.78
TNF-Mediated Restriction of Arginase 1 Expression in Myeloid Cells Triggers Type 2 NO Synthase Activity at the Site of Infection. Cell Rep (2016) 0.78
Induction of suppressor macrophages in mice by Fusarenon-X. Immunology (1982) 0.77
Adjuvants et stimulants de l'immunité: propriétés immunorégulatrices du muramyl-dipeptide, des corynébactéries anaérobies et du diéthyldithiocarbamate de sodium. Can Vet J (1988) 0.75
Effect of Corynebacterium parvum-mediated inhibition of lymphocyte proliferation on the effector- and suppressor-lymphocyte response in contact allergy. Arch Dermatol Res (1982) 0.75
Antitumour activity of spleen extract. Can Med Assoc J (1981) 0.75
Modulation of mitogenic responsiveness by staphylococcal peptidoglycan. Infect Immun (1980) 0.75
Enhanced resistance of mice to Mycoplasma pulmonis-induced arthritis by administration of killed Corynebacterium parvum. Clin Exp Immunol (1981) 0.75
Investigation of the component of Propionibacterium acnes (Corynebacterium parvum) responsible for macrophage activation. Infect Immun (1980) 0.75
Natural cell-mediated immunity. Adv Cancer Res (1978) 5.53
Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer (1975) 3.54
Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26
Antiviral effects of recombinant tumour necrosis factor in vitro. Nature (1986) 3.25
Natural killer cells: characteristics and regulation of activity. Immunol Rev (1979) 3.14
The immunobiology of zinc. Immunol Today (1997) 2.93
Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol (1979) 2.80
High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis (1998) 2.48
Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology (2000) 2.46
Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med (1974) 2.40
Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic target cells. Int J Cancer (1977) 2.39
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol (2004) 2.07
Interferon-gamma production by Listeria monocytogenes-specific T cells active in cellular antibacterial immunity. Eur J Immunol (1983) 2.06
Low density of Thy 1 antigen on mouse effector cells mediating natural cytotoxicity against tumor cells. J Immunol (1978) 2.04
Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet (1990) 1.80
Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79
Inhibition of murine natural killer cell activity by prostaglandins. J Immunol (1980) 1.68
Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors. Transfus Med (2000) 1.67
Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol (1992) 1.66
Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. J Immunol (1975) 1.62
Failure to detect human cytomegalovirus DNA in peripheral blood leukocytes of healthy blood donors by the polymerase chain reaction. Transfusion (1992) 1.60
Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol (1995) 1.58
Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand (1988) 1.57
Interferon treatment inhibits onset of herpes simplex virus immediate-early transcription. Virology (1988) 1.55
Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol (1996) 1.55
Fc receptors on mouse effector cells mediating natural cytotoxicity against tumor cells. J Immunol (1977) 1.53
Two functionally distinct anti-tumor effector cells isolated from primary murine sarcoma virus-induced tumors. J Immunol (1976) 1.53
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50
Role of macrophages in the augementation of mouse natural killer cell activity by poly I:C and interferon. J Immunol (1979) 1.49
Identification and separation of Thy-1 positive mouse spleen cells active in natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity. J Immunol (1979) 1.48
Altered cytokine production in the elderly. Mech Ageing Dev (1998) 1.47
Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro. J Immunol (1979) 1.46
Production of immune interferon by murine T-cell clones from long-term cultures. Nature (1981) 1.45
Natural cell-mediated cytotoxicity in mice against non-lymphoid tumor cells and some normal cells. Int J Cancer (1977) 1.42
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer (2001) 1.42
Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry (1996) 1.41
[An interuniversity comparison of the supervision of doctoral candidates--should the promotion procedures be changed?]. Dtsch Med Wochenschr (2000) 1.40
Natural cell-mediated cytotoxicity in rats. II. In vivo augmentation of NK-cell activity. Int J Cancer (1978) 1.38
Coincidence of neonatal alloimmune thrombocytopenia and maternal anti-D immunization: case report. Br J Haematol (1998) 1.37
Direct augmentation of cytolytic activity of tumor-derived macrophages and macrophage cell lines by muramyl dipeptide. Cell Immunol (1979) 1.37
The detection of human cytomegalovirus immediate early antigen in peripheral blood leucocytes. J Immunol Methods (1991) 1.35
The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods (2000) 1.34
Kinetics of the Zn 2+ - stimulation of human peripheral lmphocytes in vitro. Proc Soc Exp Biol Med (1971) 1.34
Identification of herpes simplex virus type 1 (HSV-1) glycoprotein gC as the immunodominant antigen for HSV-1-specific memory cytotoxic T lymphocytes. J Immunol (1985) 1.28
Genetic variability of herpes simplex virus: development of a pathogenic variant during passaging of a nonpathogenic herpes simplex virus type 1 virus strain in mouse brain. J Virol (1983) 1.27
Antiviral activity of tumour necrosis factor. Synergism with interferons and induction of oligo-2',5'-adenylate synthetase. J Gen Virol (1988) 1.26
Experimental infection of inbred mice with herpes simplex virus type 1. I. Investigation of humoral and cellular immunity and of interferon induction. J Gen Virol (1981) 1.25
Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta. J Interferon Cytokine Res (1999) 1.24
In vitro mitogenic stimulation of murine spleen cells by herpes simplex virus. J Immunol (1978) 1.24
Replication of herpes simplex virus in human T lymphocytes: characterization of the viral target cell. J Immunol (1984) 1.24
Reactivity of anti-asialo GM1 serum with tumoricidal and non-tumoricidal mouse macrophages. J Leukoc Biol (1985) 1.23
Zinc-altered immune function and cytokine production. J Nutr (2000) 1.22
The effects of general anesthesia on human peripheral immune cell distribution and cytokine production. Clin Immunol Immunopathol (1997) 1.21
Natural killer cells as antitumor effector cells. J Natl Cancer Inst (1979) 1.21
Prostaglandin synthesis in spleen cell cultures of mice injected with Corynebacterium parvum. Cell Immunol (1978) 1.20
Human cytomegalovirus replicates in primary human bone marrow cells. J Gen Virol (1986) 1.18
Cytokine production and serum proteins in depression. Scand J Immunol (1995) 1.18
Experimental infection of inbred mice with herpes simplex virus. V. Investigations with a virus strain non-lethal after peripheral infection. J Gen Virol (1982) 1.18
Rapid HLA-DRB1 genotyping by nested PCR amplification. Tissue Antigens (1992) 1.16
Pokeweed mitogen-, concanavalin A-, and phytohemagglutinin-induced development of cytotoxic effector lymphocytes. An evaluation of the mechanisms of T cell-mediated cytotoxicity. J Exp Med (1973) 1.16
The role of interferon in the resistance of C57BL/6 mice to various doses of herpes simplex virus type 1. J Infect Dis (1982) 1.16
Inhibition of the mixed lymphocyte culture by peritoneal exudate cells. Cell Immunol (1976) 1.15
Stimulation of chicken lymphocytes in a serum-free medium. Cell Immunol (1972) 1.15
Mycoplasma contamination in human tumor cell lines: effect on interferon induction and susceptibility to natural killing. J Immunol (1981) 1.13
Endotoxin requirement for macrophage activation by lymphokines in a rapid microcytotoxicity assay. J Immunol Methods (1980) 1.10
Dysregulation between TH1 and TH2 T cell subpopulations in the elderly. Mech Ageing Dev (1996) 1.08
Clonal analysis of human T cell activation by the Mycoplasma arthritidis mitogen (MAS). Eur J Immunol (1988) 1.08
An X-linked locus influences the amount of circulating interferon induced in the mouse by herpes simplex virus type 1. J Gen Virol (1982) 1.08
A reappraisal of the effector cells mediating mitogen induced cellular cytotoxicity. Cell Immunol (1975) 1.08
Cytomegalovirus transcripts in peripheral blood leukocytes of actively infected transplant patients detected by reverse transcription-polymerase chain reaction. J Infect Dis (1993) 1.07
Inflammatory markers in major depression and melancholia. J Affect Disord (2001) 1.07
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol (2008) 1.06
Natural killer cell activity in the rat. Analysis of effector cell morphology and effects of interferon on natural killer cell function in the athymic (nude) rat. Eur J Immunol (1982) 1.06
Inhibition of in vitro lymphoproliferative responses to tumor-associated antigens by suppressor cells from rats bearing progressively growing Gross leukemia virus-induced tumors. Int J Cancer (1975) 1.05
Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry (2001) 1.05
Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. J Clin Microbiol (2001) 1.05
Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. Stem Cells Dev (2004) 1.04
Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation (1995) 1.04
Protection against herpes simplex virus infection in mice by Corynebacterium parvum. Infect Immun (1977) 1.04
Stimulation of human peripheral lymphocytes by Zn2+ in vitro. Exp Cell Res (1970) 1.04
Recent progress in the tumor necrosis factor-alpha field. Int Arch Allergy Immunol (1996) 1.03
Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer (1999) 1.03
A whole-blood technique for testing production of human interferon by leukocytes. J Immunol Methods (1982) 1.03
Human peripheral null lymphocytes. II. Producers of type-1 interferon upon stimulation with tumor cells, Herpes simplex virus and Corynebacterium parvum. Eur J Immunol (1980) 1.02
Production of an antiviral factor by murine spleen cells after treatment with Corynebacterium parvum. Cell Immunol (1977) 1.02
Production of immune interferon is regulated by more than T cell subset: Lyt-1,2,3 and Qat-5 phenotypes of murine T lymphocytes involved in IFN-gamma production in primary and secondary mixed lymphocyte reaction. Eur J Immunol (1982) 1.02
Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol (1999) 1.02
Experimental infection of inbred mice with herpes simplex virus. II. Interferon production and activation of natural killer cells in the peritoneal exudate. J Gen Virol (1981) 1.02
Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations. Transfusion (2000) 1.02
Cytokine production after helium-neon laser irradiation in cultures of human peripheral blood mononuclear cells. J Photochem Photobiol B (1992) 1.01
Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol (1995) 1.01
Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry (1999) 1.01
A human whole-blood assay for analysis of T-cell function by quantification of cytokine mRNA. Scand J Immunol (1999) 1.01
Immunobiology of human papillomavirus infection. Prog Med Virol (1986) 1.00
The production of a monocyte chemotactic factor by agammaglobulinemic chicken spleen cells. J Immunol (1972) 1.00
Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol (1999) 1.00
Production of colony-stimulating factors by Hodgkin cell lines. Int J Cancer (1983) 1.00